Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.

Nat Med 2016 Mar 1;22(3):262-9. Epub 2016 Feb 1.

Massachusetts General Hospital (MGH) Cancer Center, Charlestown, Massachusetts, USA.

Although mechanisms of acquired resistance of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancers to EGFR inhibitors have been identified, little is known about how resistant clones evolve during drug therapy. Here we observe that acquired resistance caused by the EGFR(T790M) gatekeeper mutation can occur either by selection of pre-existing EGFR(T790M)-positive clones or via genetic evolution of initially EGFR(T790M)-negative drug-tolerant cells. The path to resistance impacts the biology of the resistant clone, as those that evolved from drug-tolerant cells had a diminished apoptotic response to third-generation EGFR inhibitors that target EGFR(T790M); treatment with navitoclax, an inhibitor of the anti-apoptotic factors BCL-xL and BCL-2 restored sensitivity. We corroborated these findings using cultures derived directly from EGFR inhibitor-resistant patient tumors. These findings provide evidence that clinically relevant drug-resistant cancer cells can both pre-exist and evolve from drug-tolerant cells, and they point to therapeutic opportunities to prevent or overcome resistance in the clinic.

Download full-text PDF

Source
http://www.nature.com/articles/nm.4040
Publisher Site
http://dx.doi.org/10.1038/nm.4040DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900892PMC
March 2016
77 Reads

Publication Analysis

Top Keywords

drug-tolerant cells
12
factor receptor
8
egfr inhibitors
8
acquired resistance
8
growth factor
8
epidermal growth
8
path resistance
4
provide evidence
4
cancer cells
4
cells path
4
drug-resistant cancer
4
resistance impacts
4
impacts biology
4
resistant clone
4
findings provide
4
biology resistant
4
gatekeeper mutation
4
occur selection
4
cells
4
clinically relevant
4

References

(Supplied by CrossRef)

TS Mok et al.
N. Engl. J. Med. 2009

M Maemondo et al.
N. Engl. J. Med. 2010

DR Camidge et al.
Nat. Rev. Clin. Oncol. 2014

LV Sequist et al.
Sci. Transl. Med. 2011

W Pao et al.
PLoS Med. 2005

JA Engelman et al.
Science 2007

AB Turke et al.
Cancer Cell 2010

HE Bhang et al.
Nat. Med. 2015

KY Su et al.
J. Clin. Oncol. 2012

X Ye et al.
J. Thorac. Oncol. 2013

SV Sharma et al.
Cell 2010

Similar Publications